Skip to main content

Table 1 Osteoporosis features in the study analysis population as a function of diagnostic criterion for osteoporosis

From: Management of osteoporosis and associated quality of life in post menopausal women

  Low BMD only
N = 752
Fracture only
N = 189
Both low BMD and fracture
N = 365
p Total
N = 1,306
Age at inclusion
(mean ± SD; years)
N = 750
64.3 ± 8.4
N = 189
70.6 ± 9.6
N = 365
67.7 ± 8.671
≤ 0.001 N = 1304
66.2 ± 8.9
Age at menopause
(mean ± SD; years)
N = 745
49.8 ± 4.0
N = 187
50.0 ± 3.6
N = 360
49.3 ± 4.3
0.218 N = 1290
49.7 ± 4.0
Time since menopause
(mean ± SD; years)
N = 745
14.5 ± 8.7
N = 187
20.6 ± 9.5
N = 360
18.3 ± 9.9
≤ 0.001 N = 1290
16.5 ± 9.4
At least one risk factor for osteoporosis 564 (75.0%) 156 (82.5%) 308 (84.4%) ≤ 0.001 1,028 (78.7%)
Osteoporosis treatment ongoing at time of consultation 427 (56.8%) 118 (62.4%) 240 (65.8%) 0.016 785 (60.1%)
Nature of ongoing treatment N = 407 N = 111 N = 228   N = 746
   Bisphosphonates 295 (72.5%) 084 (75.7%) 164 (71.9%) 0.895 543 (72.8%)
   Selective estrogen receptor modulator 53 (13.0%) 7 (6.3%) 16 (7.0%) 0.023 76 (10.2%)
   Strontium ranelate 54 (13.3%) 18 (16.2%) 47 (20.6%) 0.062 119 (16.0%)
   Other 14 (3.5%) 6 (5.4%) 6 (2.7%) 0.056 26 (3.5%)
Calcium or vitamin D supplementation N = 597
609 (82.3%)
N = 153
161 (86.6%)
N = 324
316 (87.8%)
0.008 N = 1064
1086 (84.5%)
  1. Data are presented as mean ± SD for quantitative variables and as numbers of women (%) for categorical variables. Between group differences were determined with the Kruskal-Wallis test or Fisher's exact test, as appropriate.